Hyperfine, Inc.

Hyperfine, Inc.

HYPR
Hyperfine, Inc.US flagNASDAQ Global Market
0.81
USD
-0.02
- -
68.49MMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
0.41
0.1
0.15
0.18
0.17
0.18
Basic EPS, GAAP
-0.28
-0.33
-17.57
-1.04
-0.62
-0.56
-0.43
-0.38
Free Cash Flow per Basic Share
-0.27
-0.33
-13.52
-1.04
-0.6
-0.54
-0.36
-0.3
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.57
-0.87
2.65
1.75
1.17
0.67
0.42
0.35
Tangible Book Value per Share
-0.57
-0.87
2.65
1.75
1.17
0.67
0.42
0.35
Basic Weighted Avg Shares
70
70
4
70
71
72
82
93
Sales/Revenue/Turnover
- -
- -
1
7
11
13
14
17
Operating Margin (%)
- -
-7,990.14
-4,336.1
-1,084.15
-436.14
-335.33
-273.43
-203.27
Depreciation Expense
- -
- -
1
1
1
1
1
1
Net Income, GAAP
-19
-23
-65
-73
-44
-41
-36
-35
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-7,968.37
-4,334.96
-1,073.73
-401
-315.9
-262.29
-210.75
Working Capital
26
64
182
120
80
45
39
50
LT Debt
- -
- -
- -
- -
- -
- -
- -
13
Total Equity
-40
-61
186
124
84
49
41
37
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-47.21
-42.51
-61.03
-79.01
-96.97

Capital Structure

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
13
13
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
97
99
106
Market Capitalization
95
106
143

Working Capital

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
51
56
59
Cash, Cash Equivalents & STI
35
41
43
Accounts Receivable, Net
5
4
4
Inventories
7
6
7
Total Current Liabilities
12
10
10
Payables & Accruals
6
7
5
ST Debt
- -
- -
- -
Deferred Revenue
3
2
3

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-105.73%
-16.38%
Free Cash Flow
- -
17.38%
-25.59%
Net Income, GAAP
- -
25.9%
-12.64%
Sales/Revenue/Turnover
- -
169.66%
5.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3
4
4
2
13
2025
2
3
3
5
14
2026
4
4
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.14
-0.14
-0.14
-0.14
-0.56
2025
-0.12
-0.12
-0.14
-0.06
-0.43
2026
-0.09
-0.09
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Maria Degois Sainz
Full Time Employees
102
Sector
Healthcare
Industry
Medical - Devices
Address
351 New Whitfield Street Guilford CT United States of America 06437
IPO Date
Jan 28, 2021
Business
Hyperfine, Inc. (Nasdaq: HYPR) develops, manufactures, and commercializes portable magnetic resonance imaging (MRI) systems for point-of-care brain imaging; its flagship Swoop Portable MR Imaging System, powered by Optive AI software, operates at ultra-low field strength (0.064T) to produce diagnostic-quality images including T1, T2, FLAIR, and DWI sequences in axial, coronal, and sagittal planes without requiring specialized infrastructure or shielding; the company also provides Hyperfine Image Viewer cloud platform for image archiving and management, technical support services, and software updates. Founded in 2014 by Jonathan Rothberg and headquartered in Guilford, Connecticut, Hyperfine targets hospitals (ICUs, emergency departments, neurology), clinics, pediatrics, stroke centers, and research institutions with its wheeled, AI-enhanced systems that enable bedside scanning globally. In 2025, Hyperfine secured FDA clearance and launched commercial sales of its next-generation Swoop system with Optive AI for substantially improved image quality; introduced the PULSE platform to accelerate AI-powered MRI adoption; announced first patient enrollments in PRIME, PRISM PMR, and NEURO PMR clinical studies evaluating portable MRI in emergency departments, operating rooms, and neurology offices; received a $3.7 million grant for global brain health initiatives and a CE Mark/UKCA approval for Optive AI to expand in Europe; expanded distribution partnerships in Turkey, Israel, Saudi Arabia, India, and additional European/Middle Eastern markets; and completed $17.5 million and $6.0 million offerings to support commercialization, manufacturing, and R&D.

Company News

  • Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference

  • Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

  • Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

  • Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

  • Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

  • Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript

  • Hyperfine Q2 Earnings Call Highlights

  • Hyperfine, Inc. Reports Second Quarter 2026 Financial Results

  • Hyperfine Announces the Release of Multiple Peer-Reviewed Publications, Expanding Clinical Evidence for the Swoop® System Across a Growing Number of Sites of Care

  • Hyperfine, Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026

  • Hyperfine Announces European Launch of Next-Generation Swoop® System

  • Hyperfine Forms Global Neurosurgery Advisory Council to Support Expansion of Portable MRI in Neurosurgical Care

  • Hyperfine Swoop® System Scan Volume in the United States Hits Record Milestones Across Multiple Sites of Care

  • Hyperfine Swoop® System Scan Volume in the United States Hits Record Milestones Across Multiple Sites of Care

  • Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript

  • Hyperfine to Join Russell 2000® and Russell 3000® Indexes

  • Hyperfine to Join Russell 2000® and Russell 3000® Indexes

  • Hyperfine Announces Presentation of Results from the PRIME Study Showing Portable MRI Substantially Reduces Time to Imaging in Emergency Departments

  • Hyperfine, Inc. (HYPR) Q1 2026 Earnings Call Transcript

  • Hyperfine Q1 Earnings Call Highlights